Schedule 13G ownership disclosure

Aardvark Therapeutics Inc

Common Stock, par value $0.00001 per share (the "Shares") · CUSIP: 002942100

Event date: 2025-02-14

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Citadel Advisors LLC

    Shares: 1,152,375.00 · Class: 5.4%

  • Citadel Advisors Holdings LP

    Shares: 1,152,375.00 · Class: 5.4%

  • Citadel GP LLC

    Shares: 1,152,375.00 · Class: 5.4%

  • Citadel Securities LLC

    Shares: 40,596.00 · Class: 0.2%

  • Citadel Securities Group LP

    Shares: 40,596.00 · Class: 0.2%

  • Citadel Securities GP LLC

    Shares: 40,596.00 · Class: 0.2%

  • Kenneth Griffin

    Shares: 1,192,971.00 · Class: 5.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-016592
Form type
SCHEDULE 13G
Filer
Aardvark Therapeutics, Inc.
CIK
CIK 1774857
Filed
Feb 24, 2025
Reporting period
Feb 14, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub